4178 — StemCyte International Share Price
0.000.00%
Last trade - 00:00- TWD4.10bn
- TWD2.26bn
- TWD382.69m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.37 | ||
| Price to Tang. Book | 2.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.23% | ||
| Return on Equity | -11.28% | ||
| Operating Margin | -67.89% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | n/a | n/a | 347.69 | 362.78 | 382.69 | n/a | n/a | 4.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
StemCyte International Ltd is a Cayman Islands-based regenerative therapeutics company offering cord blood banking, clinical stem cell therapy, and regenerative medicine. It is engaged in regenerative cell therapy and focuses on developing cell therapy products as well as providing both public and private cell banking services in the United States of America and Taiwan. It focuses on umbilical cord blood banking and is continuously developing cell therapy indications with the goal of sustainable business operations. It provides allogeneic cell materials to create solutions for cellular therapy. The Company is expanding the application of cell therapy in the development of new drugs. Its ongoing human trials include Phase II clinical trials for COVID-19, Phase II clinical trials for spinal cord injury, and Phase I clinical trials for acute stroke. Its umbilical cord blood cell therapy, RegeneCyte, has assisted in over 2,300 transplant treatments worldwide.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- June 26th, 2013
- Public Since
- December 5th, 2024
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 215,866,981
- Address
- Ugland House, GRAND CAYMAN, KY1-1104
- Web
- https://stemcytebio.com/
- Phone
- Auditors
- Deloitte & Touche LLP
Upcoming Events for 4178
StemCyte International Ltd Annual Shareholders Meeting
Similar to 4178
Abnova Taiwan
Taiwan Stock Exchange
Applied BioCode
Taiwan Stock Exchange
Energenesis Biomedical Co
Taiwan Stock Exchange
Genomics Bioscience & Technology Co
Taiwan Stock Exchange
Kim Forest Enterprise Co
Taiwan Stock Exchange
FAQ
What is the StemCyte International share price?
As of Today at 23:28 UTC, shares in StemCyte International are trading at TWD19.00. This share price information is delayed by 15 minutes.
How has the StemCyte International share price performed this year?
Shares in StemCyte International last closed at TWD19.00 and the price had moved by -30.4% over the past 365 days. In terms of relative price strength the StemCyte International share price has underperformed the FTSE Developed Asia Pacific Index by -61.06% over the past year.
What are the analyst and broker recommendations for StemCyte International?
There is no consensus recommendation for this security.
Find out moreWhat is the StemCyte International dividend yield?
StemCyte International does not currently pay a dividend.
Does StemCyte International pay a dividend?
StemCyte International does not currently pay a dividend.
When does StemCyte International next pay dividends?
StemCyte International does not currently pay a dividend.
How do I buy StemCyte International shares?
To buy shares in StemCyte International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of StemCyte International?
As of the previous close price of TWD19.00, shares in StemCyte International had a market capitalisation of TWD4.10bn.
Where are StemCyte International shares listed?
Here are the trading details for StemCyte International:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 4178
What kind of share is StemCyte International?
Based on an overall assessment of its quality, value and momentum StemCyte International is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a StemCyte International share price forecast for 2026?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the StemCyte International share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like StemCyte International. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -45.07%.
As of the last closing price of TWD19.00, shares in StemCyte International were trading -26.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the StemCyte International PE Ratio?
The StemCyte International PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD19.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of StemCyte International?
We do not have data on StemCyte International's directors